This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
by Zacks Equity Research
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA
by Zacks Equity Research
Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.
AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints
by Zacks Equity Research
AbbVie's (ABBV) new oral anti-CGRP drug, Qulipta, demonstrates potential to reduce monthly migraine days in adults with chronic migraine in a phase III study.
TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure
by Indrajit Bandyopadhyay
The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.
Teva's (TEVA) Q3 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Teva Pharmaceutical Industries' (TEVA) shares decline after the company misses both earnings and sales estimates for third-quarter 2021. Meanwhile, it reaffirms its 2021 guidance.
J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drug
by Zacks Equity Research
J&J (JNJ) gets FDA approval for its twice-a-year treatment option for schizophrenia patients, Invega Hafyera.
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. Stock up.
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.
TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up
by Zacks Equity Research
TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.
Teva Pharmaceutical Industries Ltd. (TEVA) Moves 7.5% Higher: Will This Strength Last?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.
TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down
by Zacks Equity Research
TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
by Indrajit Bandyopadhyay
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
Glaxo (GSK) Begins Late-Stage Severe Eosinophilic Asthma Study
by Zacks Equity Research
Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
TEVA Stock Declines Despite Q4 Earnings and Sales Beat
by Zacks Equity Research
TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.
TEVA Q4 Earnings & Sales Beat Estimates, Stock Rises
by Zacks Equity Research
TEVA beats earnings and sales for fourth-quarter 2020. It issues its financial guidance for 2021. Stock up
Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TEVA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.
Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate
by Zacks Equity Research
Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.
3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.